Sunday, June 1, 2025
21.5
C
Bengaluru
My account
Get into your account.
Hot topics
5 L&D Megatrends
2017 Learning and Development Special Issue. Articles by K. Hariram, Diksha Fouzdar and Vivek Hattangadi.
Sales Force Strategy in the Digital World
Does Your Company Have a Well Thought-out Strategy on...
Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World
Last week, I was in a meeting with the...
Have Tech Advances Made UCPMP Obsolete? Need for Contemporary Pharma Marketing Code
Salil Kallianpur
The code of conduct for ethical pharmaceutical marketing...
Time for Pharma to Re-think its Way of Working
https://www.youtube.com/watch?v=BOO_CNxEzwQ
Too many Medical Reps are chasing too few doctors,...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Hot topics
What my Sabziwali taught me about the Internet, Mobile Health & Smartphones
It’s very common for a pharma professional having neighbors, friends and relatives to engage in conversation over medicines. One such conversation – a pleasant surprise – which intrigued me to dig deep into internet dynamics was one with the local roadside Sabziwali.
Going Digital – What Indian Pharma C-Suite has to Say
Any transformational initiative must be driven by the CEO...
DeepSeek – A Precursor to Patent Disruption?
The rise of open-source platforms, such as China’s DeepSeek...
5 L&D Megatrends
2017 Learning and Development Special Issue. Articles by K. Hariram, Diksha Fouzdar and Vivek Hattangadi.
Partner Don’t Punish
Articles by Vivek Hattangadi, Genesh Kuriakose, Pankaj Mehrotra, Salil Kallianpur and Jay Mehta
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Indian Pharma Market Performance – April 2025
The Indian Pharmaceutical Market (IPM) maintained moderate growth in...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Semaglutide – More Than Just a Patent Battle
The Delhi High Court has restrained Dr. Reddy’s and...
Novo Nordisk — Septerna’s $2.2 Billion Deal
A New Era for Obesity Pills
Novo Nordisk has announced...
Will TATA Succeed in Reinventing Indian Pharma Retail through 1 MG Hybrid?
Tata 1mg App Business Model: How does it work...
GSK Bets Big on Liver Disease: $1.2B Upfront for Boston Pharma’s MASH Drug
In a bold move to strengthen its hepatology pipeline,...
Newsletter
Get important news delivered directly to your inbox and stay connected!